Hepatitis B Annual

REVIEW ARTICLE
Year
: 2012  |  Volume : 9  |  Issue : 1  |  Page : 16--48

Antituberculosis therapy in patients with hepatitis B viral infection


Nikhil D Patel1, Shivaram Prasad Singh2 
1 Jivandeep Hospital, Anand, Gujarat, India
2 Department of Gastroenterology, S.C.B. Medical College, Cuttack, India

Correspondence Address:
Nikhil D Patel
Jivandeep Hospital, Station Road, Anand - 388001, Gujarat
India

Tuberculosis (TB) and Hepatitis B virus (HBV) infections are quite common in the developing world especially South Asia. As both are so common, co-infection is not very uncommonly encountered in clinical practice. However, since anti-tuberculosis therapy (ATT) can be hepatotoxic in around 10% of patients, the occurrence of hepatotoxicity can complicate management especially in the presence of already compromised liver function due to HBV. Therefore, co-infection of TB and HBV is an important public health issue. Unfortunately the regional and National hepatology societies of South Asia have not bothered to provide any guidance in this matter. This article reviews the epidemiology and management of co-infection with Tuberculosis (TB) and Hepatitis B virus (HBV) and the hepatotoxicity due to ATT.


How to cite this article:
Patel ND, Singh SP. Antituberculosis therapy in patients with hepatitis B viral infection.Hep B Annual 2012;9:16-48


How to cite this URL:
Patel ND, Singh SP. Antituberculosis therapy in patients with hepatitis B viral infection. Hep B Annual [serial online] 2012 [cited 2019 Aug 17 ];9:16-48
Available from: http://www.hepatitisbannual.org/article.asp?issn=0972-9747;year=2012;volume=9;issue=1;spage=16;epage=48;aulast=Patel;type=0